Figure 3
From: FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate
FOXA2 expression in treatment-naive prostate cancers. (a) Representative images of FOXA2 immunohistochemistry staining intensity (from 0, no staining to 3, the strongest staining) on the tissue microarrays including benign prostate tissue (Benign Prostate), primary prostate adenocarcinoma (Primary Adenocarcinoma) with Gleason score 3+3, 3+4, 4+3, 8, and 9–10, Lymph node-positive prostate cancer (LN+ Adenocarcinoma), primary small cell neuroendocrine prostate cancer (primary SCNC). The numbers of each samples are 149 of Benign prostate, 73 of Gleason 3+3, 53 of Gleason 3+4, 14 of Gleason 4+3, 3 of Gleason 8, and 8 of Gleason 9–10. (b) A plot of FOXA2 immunohistochemistry staining intensity (from 0, no staining to 3, the strongest staining) in the treatment-naive prostate cancers. (c) A plot of Quick-score for FOXA2 (the intensity of staining x the percentage of staining) in the treatment-naive prostate cancers. Adeno, adenocarcinoma. LN+ Adeno, adenocarcinoma in lymph node.
